Search results
Results From The WOW.Com Content Network
Because of its long elimination half-life, dutasteride requires 5 to 6 months to reach steady-state concentrations. [59] It also remains in the body for a long time after discontinuation and can be detected up to 4 to 6 months. [1] [2] In contrast to dutasteride, finasteride has a short terminal half-life of only 5 to 8 hours.
Dutasteride is also used in the treatment of male pattern hair loss and appears to have better effectiveness than finasteride for the condition. [27] [28] [29] While used off-label for male pattern hair loss in most of the world, dutasteride is specifically approved for this indication in South Korea and Japan. [30] [31]
Dutasteride (brand name Avodart) inhibits all three 5α-reductase isoenzymes and can decrease DHT levels by 95%. [9] [10] It can also reduce DHT levels in the prostate by 97 to 99% in men with prostate cancer. [11] [12] Epristeride (brand names Aipuliete, Chuanliu) is marketed in China for the treatment of benign prostatic hyperplasia.
Postoperative cognitive dysfunction (POCD) is a decline in cognitive function (especially in memory and executive functions) that may last from 1–12 months after surgery, or longer. [1] In some cases, this disorder may persist for several years after major surgery. [ 2 ]
There are no known long-term side effects of tadalafil. In fact, studies have shown this medication is well tolerated over the long term (if you can handle the shorter-term side effects).
Medication discontinuation is the ceasing of a medication treatment for a patient by either the clinician or the patient themself. [1] [2] When initiated by the clinician, it is known as deprescribing. [3]
Postanesthetic shivering is one of the leading causes of discomfort in patients recovering from general anesthesia. It usually results due to the anesthetic inhibiting the body's thermoregulatory capability, although cutaneous vasodilation (triggered by post-operative pain) may also be a causative factor.
Bicalutamide is used primarily in the treatment of early and advanced prostate cancer. [1] It is approved at a dosage of 50 mg/day as a combination therapy with a gonadotropin-releasing hormone analogue (GnRH analogue) or orchiectomy (that is, surgical or medical castration) in the treatment of stage D2 metastatic prostate cancer (mPC), [2] [3] and as a monotherapy at a dosage of 150 mg/day ...